Why the study?
Does amlodipine/benazepril combination therapy improve endothelial function and blood pressure compared to amlodipine monotherapy in hypertensive subjects with endothelial dysfunction risk factors?
Does amlodipine/benazepril combination therapy improve endothelial function and blood pressure compared to amlodipine monotherapy in hypertensive subjects with endothelial dysfunction risk factors?
Amlodipine/benazepril combination therapy provides superior blood pressure reduction compared to amlodipine monotherapy, although it does not significantly improve endothelial function beyond the effects of monotherapy.
Answers are grounded in this paper and cite their sources.
Combination yielded no significant FMD advantage over monotherapy despite greater BP reduction; leaves open additive endothelial benefit in larger trials.
Evidence suggests that renin-angiotensin-aldosterone system inhibition ameliorates endothelial dysfunction. The authors examined the effect of amlodipine besylate/benazepril HCl combination treatment compared with amlodipine besylate monotherapy in modulating endothelial dysfunction. This multicenter, double-blind, 12-week study randomized 70 hypertensive subjects with at least one other endothelial dysfunction risk factor to amlodipine besylate/benazepril HCl (5/20 mg/d force-titrated to 5/40 mg/d) or amlodipine besylate monotherapy (5 mg/d force-titrated to 10 mg/d). Both the combination and monotherapy produced significant median increases from baseline in percentage flow-mediated vasodilation (2.0% and 1.2%, respectively) and percentage change in percent flow-mediated vasodilation (25% and 16%, respectively). These improvements were numerically larger with combination treatment, but between-group differences did not achieve statistical significance. Reductions in systolic and diastolic blood pressure were significantly greater (P=.0452/P=.0297) with combination treatment (-18.6/-12.3 mm Hg) than with monotherapy (-14.8/-9.1 mm Hg). A highly positive correlation between change in systolic blood pressure and change in percent of flow-mediated vasodilation was demonstrated only for combination treatment.
No takes yet. Share an insight, caveat, or question.
Mohler et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: